TrialBritish journal of cancer2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
R M Glasspool et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this papertrialcites it